Ke Ding

List of Publications by Year in Descending Order

203 papers	7,362 citations	45 h-index	78 g-index
238 ext. papers	8,670 ext. citations	6.9 avg, IF	5.79 L-index

#	Paper	IF	Citations
203	Proteome-wide Identification of Off-Targets of a Potent EGFR Mutant Inhibitor.. *ACS Medicinal Chemistry Letters*, **2022**, 13, 292-297	4.3	0
202	Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR Mutants.. *ACS Medicinal Chemistry Letters*, **2022**, 13, 196-202	4.3	0
201	Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?. *Journal of Medicinal Chemistry*, **2022**,	8.3	3
200	A novel photocaged B-Raf inhibitor toward precise melanoma treatment.. *Bioorganic and Medicinal Chemistry Letters*, **2022**, 64, 128683	2.9	1
199	Identification of U937 Acute Myeloid Leukemia Cells as a Sensitive Model to JAK3 Inhibitor.. *Frontiers in Oncology*, **2021**, 11, 807200	5.3	0
198	Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.. *Journal of Medicinal Chemistry*, **2021**,	8.3	10
197	Discovery of novel TrkA allosteric inhibitors: Structure-based virtual screening, biological evaluation and preliminary SAR studies. *European Journal of Medicinal Chemistry*, **2021**, 228, 114022	6.8	1
196	LS-106, a novel EGFR inhibitor targeting C797S, exhibits anti-tumor activities both in vitro and in vivo. *Cancer Science*, **2021**,	6.9	4
195	Novel Electrophilic Warhead Targeting a Triple-Negative Breast Cancer Driver in Live Cells Revealed by "Inverse Drug Discovery". *Journal of Medicinal Chemistry*, **2021**, 64, 15582-15592	8.3	2
194	Secondary-structure switch regulates the substrate binding of a YopJ family acetyltransferase. *Nature Communications*, **2021**, 12, 5969	17.4	1
193	Characterization of an aromatic trifluoromethyl ketone as a new warhead for covalently reversible kinase inhibitor design. *Bioorganic and Medicinal Chemistry*, **2021**, 50, 116457	3.4	1
192	Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors. *ACS Medicinal Chemistry Letters*, **2021**, 12, 647-652	4.3	1
191	Glucocappasalin Induces G2/M-Phase Arrest, Apoptosis, and Autophagy Pathways by Targeting CDK1 and PLK1 in Cervical Carcinoma Cells. *Frontiers in Pharmacology*, **2021**, 12, 671138	5.6	2
190	Activation of transmembrane receptor tyrosine kinase DDR1-STAT3 cascade by extracellular matrix remodeling promotes liver metastatic colonization in uveal melanoma. *Signal Transduction and Targeted Therapy*, **2021**, 6, 176	21	6
189	GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo. *Cancer Medicine*, **2021**, 10, 4874-4884	4.8	4
188	Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors. *European Journal of Medicinal Chemistry*, **2021**, 211, 113023	6.8	3
187	Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation. *Acta Pharmaceutica Sinica B*, **2021**, 11, 1315-1328	15.5	5

186	Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer. *Nature Cancer*, **2021**, 2, 978-993	15.4	4
185	Development and application of novel electrophilic warheads in target identification and drug discovery. *Biochemical Pharmacology*, **2021**, 190, 114636	6	1
184	Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. *Journal of Medicinal Chemistry*, **2020**, 63, 10726-10741	8.3	11
183	Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors. *EMBO Molecular Medicine*, **2020**, 12, e11571	12	13
182	Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. *Molecular Cancer*, **2020**, 19, 90	42.1	16
181	2-Azirine-Based Reagents for Chemoselective Bioconjugation at Carboxyl Residues Inside Live Cells. *Journal of the American Chemical Society*, **2020**, 142, 6051-6059	16.4	44
180	Identification and characterization of N9-methyltransferase involved in converting caffeine into non-stimulatory theacrine in tea. *Nature Communications*, **2020**, 11, 1473	17.4	14
179	Design and synthesis of selective degraders of EGFR mutant. *European Journal of Medicinal Chemistry*, **2020**, 192, 112199	6.8	30
178	Copper-Mediated Diamination of Arylboronic Acids for the Synthesis of 2-Aryl Benzimidazoles Using Trimethylsilyl Azide as the Amino Sources with Aldehydes. *Advanced Synthesis and Catalysis*, **2020**, 362, 3442-3446	5.6	5
177	A patent review of discoidin domain receptor 1 (DDR1) modulators (2014-present). *Expert Opinion on Therapeutic Patents*, **2020**, 30, 341-350	6.8	5
176	The synthesis and biological evaluation of sanguinarine derivatives as anti-non-small cell lung cancer agents. *RSC Medicinal Chemistry*, **2020**, 11, 293-296	3.5	1
175	Allosterische Kinaseinhibitoren Erwartungen und Chancen. *Angewandte Chemie*, **2020**, 132, 13868-13883	3.6	0
174	Quantitative Proteomics Reveals Cellular Off-Targets of a DDR1 Inhibitor. *ACS Medicinal Chemistry Letters*, **2020**, 11, 535-540	4.3	6
173	GZD824 as a FLT3, FGFR1 and PDGFR Inhibitor Against Leukemia In Vitro and In Vivo. *Translational Oncology*, **2020**, 13, 100766	4.9	9
172	Small-Molecule CSF1R Inhibitors as Anticancer Agents. *Current Medicinal Chemistry*, **2020**, 27, 3944-3966	4.3	17
171	New Promise and Opportunities for Allosteric Kinase Inhibitors. *Angewandte Chemie - International Edition*, **2020**, 59, 13764-13776	16.4	45
170	Design and Optimization of 3R(Imidazo[1,2-]pyrazin-3-yl)-[1,1Rbiphenyl]-3-carboxamides as Selective DDR1 Inhibitors. *ACS Medicinal Chemistry Letters*, **2020**, 11, 379-384	4.3	6
169	Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia. *Cancer Letters*, **2020**, 472, 132-141	9.9	8

168	Applications of Activity-Based Protein Profiling (ABPP) and Bioimaging in Drug Discovery. *Chemistry - an Asian Journal*, **2020**, 15, 34-41	4.5	9
167	Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors. *European Journal of Medicinal Chemistry*, **2020**, 203, 112552	6.8	5
166	Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics. *Journal of Medicinal Chemistry*, **2020**, 63, 14404-14424	8.3	26
165	Design, Synthesis, and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as New Selective Leucine-Zipper and Sterile-□Motif Kinase (ZAK) Inhibitors. *Journal of Medicinal Chemistry*, **2020**, 63, 2114-2130	8.3	6
164	Minimalist linkers suitable for irreversible inhibitors in simultaneous proteome profiling, live-cell imaging and drug screening. *Chemical Communications*, **2019**, 55, 834-837	5.8	15
163	Integrated phenotypic screening and activity-based protein profiling to reveal potential therapy targets of pancreatic cancer. *Chemical Communications*, **2019**, 55, 1596-1599	5.8	10
162	Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). *Journal of Medicinal Chemistry*, **2019**, 62, 5944-5978	8.3	9
161	Quinolone antibiotic derivatives as new selective Axl kinase inhibitors. *European Journal of Medicinal Chemistry*, **2019**, 166, 318-327	6.8	11
160	Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors. *European Journal of Medicinal Chemistry*, **2019**, 179, 470-482	6.8	3
159	Identification of New Small-Molecule Inducers of Estrogen-related Receptor □(ERR)□Degradation. *ACS Medicinal Chemistry Letters*, **2019**, 10, 767-772	4.3	24
158	Crenolanib-Derived Probes Suitable for Cell- and Tissue-Based Protein Profiling and Single-Cell Imaging. *ChemBioChem*, **2019**, 20, 1783-1788	3.8	3
157	Identification of Pyrazolo[1,5-]pyridine-3-carboxamide Diaryl Derivatives as Drug Resistant Antituberculosis Agents. *ACS Medicinal Chemistry Letters*, **2019**, 10, 295-299	4.3	10
156	A novel reactive turn-on probe capable of selective profiling and no-wash imaging of Bruton□s tyrosine kinase in live cells. *Chemical Communications*, **2019**, 55, 3473-3476	5.8	11
155	2-Amino-2,3-dihydro-1-indene-5-carboxamide-Based Discoidin Domain Receptor 1 (DDR1) Inhibitors: Design, Synthesis, and in Vivo Antipancreatic Cancer Efficacy. *Journal of Medicinal Chemistry*, **2019**, 62, 7431-7444	8.3	23
154	Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR). *Journal of Medicinal Chemistry*, **2019**, 62, 7302-7308	8.3	21
153	Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4. *ACS Medicinal Chemistry Letters*, **2019**, 10, 1180-1186	4.3	12
152	Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases. *Journal of Medicinal Chemistry*, **2019**, 62, 8951-8952	8.3	13
151	Affinity-Based Protein Profiling Reveals Cellular Targets of Photoreactive Anticancer Inhibitors. *ACS Chemical Biology*, **2019**, 14, 2546-2552	4.9	13

150	Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. *Journal of Medicinal Chemistry*, **2019**, 62, 2905-2915	8.3	36
149	GZD2202, a novel TrkB inhibitor, suppresses BDNF-mediated proliferation and metastasis in neuroblastoma models. *Journal of Drug Targeting*, **2019**, 27, 442-450	5.4	1
148	Pyrazolo[1,5- a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis. *ACS Infectious Diseases*, **2019**, 5, 239-249	5.5	47
147	Design, Synthesis, and Structure-Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 2353-2371	8.3	13
146	Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer. *European Journal of Medicinal Chemistry*, **2018**, 152, 542-559	6.8	15
145	Overexpression of ZAK□n human osteosarcoma cells enhances ZAK□expression, resulting in a synergistic apoptotic effect. *Cell Biochemistry and Function*, **2018**, 36, 176-182	4.2	1
144	YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR -mutant resistance in vitro and in vivo. *Cancer Medicine*, **2018**, 7, 1430-1439	4.8	1
143	Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer. *European Journal of Medicinal Chemistry*, **2018**, 147, 238-252	6.8	34
142	Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer. *ACS Medicinal Chemistry Letters*, **2018**, 9, 262-267	4.3	9
141	Targeting EGFR and EGFR resistance mutations in NSCLC: Current developments in medicinal chemistry. *Medicinal Research Reviews*, **2018**, 38, 1550-1581	14.4	66
140	Structure-Based Discovery and Optimization of Benzo[d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC). *Journal of Medicinal Chemistry*, **2018**, 61, 3037-3058	8.3	25
139	Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2- a]pyrazin-3-ylethynyl)-4-isopropyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2. *Journal of Medicinal Chemistry*, **2018**, 61, 7977-7990	8.3	14
138	Rational Design and Structure Validation of a Novel Peptide Inhibitor of the Adenomatous-Polyposis-Coli (APC)-Rho-Guanine-Nucleotide-Exchange-Factor-4 (Asef) Interaction. *Journal of Medicinal Chemistry*, **2018**, 61, 8017-8028	8.3	7
137	Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement. *Cell Chemical Biology*, **2018**, 25, 206-214.e11	8.2	109
136	Discovery of JND3229 as a New EGFR Mutant Inhibitor with In Vivo Monodrug Efficacy. *ACS Medicinal Chemistry Letters*, **2018**, 9, 1123-1127	4.3	26
135	Cell- and Tissue-Based Proteome Profiling and Dual Imaging of Apoptosis Markers with Probes Derived from Venetoclax and Idasanutlin. *Angewandte Chemie - International Edition*, **2018**, 57, 9284-9289	16.4	23
134	Cell- and Tissue-Based Proteome Profiling and Dual Imaging of Apoptosis Markers with Probes Derived from Venetoclax and Idasanutlin. *Angewandte Chemie*, **2018**, 130, 9428-9433	3.6	6
133	Manganese-Catalyzed C□H Annulation of Ketimines with Allenes: Stereoselective Synthesis of 1-Aminoindanes. *Advanced Synthesis and Catalysis*, **2018**, 360, 2952-2958	5.6	11

132	Cell- and Tissue-Based Proteome Profiling and Bioimaging with Probes Derived from a Potent AXL Kinase Inhibitor. *Chemistry - an Asian Journal*, **2018**, 13, 2601-2605	4.5	6
131	Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R. *Acta Pharmacologica Sinica*, **2018**, 39, 1768-1776	8	5
130	Quantitative data describing the impact of the flavonol rutin on in-vivo blood-glucose and fluid-intake profiles, and survival of human-amylin transgenic mice. *Data in Brief*, **2017**, 10, 298-303	1.2	1
129	Novel conjugates of endoperoxide and 4-anilinoquinazoline as potential anticancer agents. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 1341-1345	2.9	2
128	Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. *ACS Medicinal Chemistry Letters*, **2017**, 8, 327-332	4.3	22
127	Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric carcinoma. *BMC Cancer*, **2017**, 17, 87	4.8	33
126	Structural insights into the binding mechanism of IDO1 with hydroxylamidine based inhibitor INCB14943. *Biochemical and Biophysical Research Communications*, **2017**, 487, 339-343	3.4	31
125	2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. *European Journal of Medicinal Chemistry*, **2017**, 135, 531-543	6.8	14
124	A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFR mutant with improved pharmacokinetic properties. *European Journal of Medicinal Chemistry*, **2017**, 126, 1107-1117	6.8	22
123	Structure Based Design of N-(3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzenesulfonamides as Selective Leucine-Zipper and Sterile-Motif Kinase (ZAK) Inhibitors. *Journal of Medicinal Chemistry*, **2017**, 60, 5927-5932	8.3	12
122	Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl inhibitor overcoming acquired imatinib resistance. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2017**, 32, 331-336	5.6	5
121	2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors. *ACS Medicinal Chemistry Letters*, **2017**, 8, 543-548	4.3	26
120	The antihelmenthic phosphate niclosamide impedes renal fibrosis by inhibiting homeodomain-interacting protein kinase 2 expression. *Kidney International*, **2017**, 92, 612-624	9.9	21
119	Tetrazole-Based Probes for Integrated Phenotypic Screening, Affinity-Based Proteome Profiling, and Sensitive Detection of a Cancer Biomarker. *Angewandte Chemie - International Edition*, **2017**, 56, 15044-15048	16.4	52
118	Tetrazole-Based Probes for Integrated Phenotypic Screening, Affinity-Based Proteome Profiling, and Sensitive Detection of a Cancer Biomarker. *Angewandte Chemie*, **2017**, 129, 15240-15244	3.6	6
117	Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma. *Molecular Cancer Therapeutics*, **2017**, 16, 2473-2485	6.1	53
116	Visualization and Quantification of Browning Using a Ucp1-2A-Luciferase Knock-in Mouse Model. *Diabetes*, **2017**, 66, 407-417	0.9	27
115	Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. *Clinical Cancer Research*, **2017**, 23, 789-803	12.9	42

114	Rutin suppresses human-amylin/hIAPP misfolding and oligomer formation in-vitro, and ameliorates diabetes and its impacts in human-amylin/hIAPP transgenic mice. *Biochemical and Biophysical Research Communications*, **2017**, 482, 625-631	3.4	19
113	Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity. *European Journal of Medicinal Chemistry*, **2017**, 125, 41-48	6.8	32
112	GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways. *Oncotarget*, **2017**, 8, 87002-87015	3.3	11
111	The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 4310-4317	3.4	13
110	Small Molecule Inhibitors of Discoidin Domain Receptors (DDRs) **2016**, 181-200		
109	Harmine Induces Adipocyte Thermogenesis through RAC1-MEK-ERK-CHD4 Axis. *Scientific Reports*, **2016**, 6, 36382	4.9	11
108	Discovery of new chemical entities as potential leads against Mycobacterium tuberculosis. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 5916-5919	2.9	21
107	Discovery of New Monocarbonyl Ligustrazine-Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer. *Journal of Medicinal Chemistry*, **2016**, 59, 1747-60	8.3	45
106	Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. *Nature Medicine*, **2016**, 22, 270-7	50.5	115
105	GZD856, a novel potent PDGFRβ inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo. *Cancer Letters*, **2016**, 375, 172-178	9.9	16
104	Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation. *Journal of Medicinal Chemistry*, **2016**, 59, 1565-79	8.3	60
103	Leucine-zipper and Sterile-α Motif Kinase (ZAK): A Potential Target for Drug Discovery. *Current Medicinal Chemistry*, **2016**, 23, 3801-3812	4.3	4
102	Antitumor activity of 7RH, a discoidin domain receptor 1 inhibitor, alone or in combination with dasatinib exhibits antitumor effects in nasopharyngeal carcinoma cells. *Oncology Letters*, **2016**, 12, 3598-3608	2.6	17
101	Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. *Journal of Medicinal Chemistry*, **2016**, 59, 5911-6	8.3	32
100	Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 2760-2763	2.9	5
99	Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 3052-3059	2.9	9
98	Up-regulation of N-cadherin by Collagen I-activated Discoidin Domain Receptor 1 in Pancreatic Cancer Requires the Adaptor Molecule Shc1. *Journal of Biological Chemistry*, **2016**, 291, 23208-23223	5.4	36
97	Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 3458-63	2.9	9

96	C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFRT790M mutant. *MedChemComm*, **2015**, 6, 1693-1697	5	20
95	Evaluation of spiropiperidine hydantoins as a novel class of antimalarial agents. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 5144-50	3.4	19
94	Aqueous synthesis of PEGylated copper sulfide nanoparticles for photoacoustic imaging of tumors. *Nanoscale*, **2015**, 7, 11075-81	7.7	56
93	N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors. *ACS Medicinal Chemistry Letters*, **2015**, 6, 543-7	4.3	21
92	1-Benzyl-4-phenyl-1H-1,2,3-triazoles improve the transcriptional functions of estrogen-related receptor □and promote the browning of white adipose. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 3751-60	3.4	7
91	Super-stable centimetre-scale inverse opal belts integrated with CdTe QDs for narrow band fluorescence optical waveguiding. *Journal of Materials Chemistry C*, **2015**, 3, 10964-10967	7.1	
90	Small molecule discoidin domain receptor kinase inhibitors and potential medical applications. *Journal of Medicinal Chemistry*, **2015**, 58, 3287-301	8.3	46
89	DC120, a novel AKT inhibitor, preferentially suppresses nasopharyngeal carcinoma cancer stem-like cells by downregulating Sox2. *Oncotarget*, **2015**, 6, 6944-58	3.3	26
88	Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFR□roles of Mcl-1 and □catenin. *Molecular Cancer*, **2014**, 13, 17	42.1	18
87	Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib. *Journal of Medicinal Chemistry*, **2014**, 57, 2692-703	8.3	24
86	Synthesis, Skeletal Rearrangement, and Biological Activities of Spirooxindoles: Exploration of a Stepwise C-Piancatelli Rearrangement. *European Journal of Organic Chemistry*, **2014**, 2014, 338-349	3.2	26
85	Detection of Epstein□Barr virus infection in cancer by using highly specific nanoprobe based on dBSA capped CdTe quantum dots. *RSC Advances*, **2014**, 4, 22545	3.7	8
84	Novel anaplastic lymphoma kinase inhibitors targeting clinically acquired resistance. *Journal of Medicinal Chemistry*, **2014**, 57, 1167-9	8.3	5
83	New benzimidazole-2-urea derivates as tubulin inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 4250-3	2.9	27
82	Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation. *Cancer Letters*, **2014**, 353, 115-23	9.9	13
81	Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors. *European Journal of Medicinal Chemistry*, **2014**, 77, 75-83	6.8	17
80	Evaluation of aminohydantoins as a novel class of antimalarial agents. *ACS Medicinal Chemistry Letters*, **2014**, 5, 89-93	4.3	25
79	SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. *Cancer Biology and Therapy*, **2014**, 15, 951-62	4.6	19

78	Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer. *Cell Death and Disease*, **2014**, 5, e1114	9.8	7
77	Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling. *Molecular Cancer Therapeutics*, **2014**, 13, 1217-30	6.1	31
76	Magnetically engineered Cd-free quantum dots as dual-modality probes for fluorescence/magnetic resonance imaging of tumors. *Biomaterials*, **2014**, 35, 1608-17	15.6	95
75	Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells. *Oncotarget*, **2014**, 5, 10407-20	3.3	7
74	Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. *Chinese Journal of Cancer*, **2014**, 33, 80-6		109
73	Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors. *European Journal of Medicinal Chemistry*, **2013**, 66, 82-90	6.8	14
72	Pyrimido[4,5-d]pyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine790 to Methionine790 (T790M) Mutants. *Angewandte Chemie*, **2013**, 125, 8545-8548	3.6	0
71	Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties. *Journal of Medicinal Chemistry*, **2013**, 56, 8803-13	8.3	22
70	Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant. *Journal of Medicinal Chemistry*, **2013**, 56, 7821-37	8.3	51
69	Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. *Journal of Medicinal Chemistry*, **2013**, 56, 879-94	8.3	75
68	Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors. *Journal of Medicinal Chemistry*, **2013**, 56, 3281-95	8.3	100
67	1-Phenyl-4-benzoyl-1H-1,2,3-triazoles as orally bioavailable transcriptional function suppressors of estrogen-related receptor β. *Journal of Medicinal Chemistry*, **2013**, 56, 4631-40	8.3	53
66	Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer. *Journal of Medicinal Chemistry*, **2013**, 56, 4738-48	8.3	52
65	Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as selective inhibitors of EGFR threonine790 to methionine790 (T790M) mutants. *Angewandte Chemie - International Edition*, **2013**, 52, 8387-90	16.4	25
64	Alleviation of podophyllotoxin toxicity using coexisting flavonoids from Dysosma versipellis. *PLoS ONE*, **2013**, 8, e72099	3.7	12
63	New thiazole carboxamides as potent inhibitors of Akt kinases. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 1208-12	2.9	26
62	A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton. *Investigational New Drugs*, **2012**, 30, 490-507	4.3	9
61	Copper-catalyzed desymmetric intramolecular Ullmann C-N coupling: an enantioselective preparation of indolines. *Journal of the American Chemical Society*, **2012**, 134, 14326-9	16.4	82

60	Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine□methionine□mutant. *Journal of Medicinal Chemistry*, **2012**, 55, 2711-23	8.3	69
59	A CuAAC/Ullmann C-C coupling tandem reaction: copper-catalyzed reactions of organic azides with N-(2-iodoaryl)propiolamides or 2-iodo-N-(prop-2-ynyl)benzenamines. *Organic Letters*, **2012**, 14, 3332-5	6.2	78
58	Design, synthesis, and in vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza A agents targeting virus nucleoprotein. *Journal of Medicinal Chemistry*, **2012**, 55, 2144-53	8.3	103
57	Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine790-methionine790 mutant. *MedChemComm*, **2012**, 3, 1155	5	16
56	Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)-isoleucine(315) mutant. *Journal of Medicinal Chemistry*, **2012**, 55, 10033-46	8.3	27
55	Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. *Chinese Journal of Cancer*, **2012**, 31, 178-84		96
54	Synthesis of [1,2,3]triazolo[1,5-a]quinoxalin-4(5H)-ones through copper-catalyzed tandem reactions of N-(2-haloaryl)propiolamides with sodium azide. *Organic Letters*, **2012**, 14, 1262-5	6.2	56
53	Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor □nd bcr-abl oncogene addiction in malignant hematologic cells. *Clinical Cancer Research*, **2012**, 18, 1966-78	12.9	35
52	DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth. *Molecular Pharmacology*, **2012**, 82, 189-98	4.3	6
51	Pharmacophore and molecular docking guided 3D-QSAR study of bacterial enoyl-ACP reductase (FabI) Inhibitors. *International Journal of Molecular Sciences*, **2012**, 13, 6620-38	6.3	12
50	Recent advance in the design of small molecular modulators of estrogen-related receptors. *Current Pharmaceutical Design*, **2012**, 18, 3421-31	3.3	19
49	BMS309403 stimulates glucose uptake in myotubes through activation of AMP-activated protein kinase. *PLoS ONE*, **2012**, 7, e44570	3.7	6
48	Copper-catalyzed tandem reactions of 1-(2-iodoary)-2-yn-1-ones with isocyanides for the synthesis of 4-oxo-indeno[1,2-b]pyrroles. *Organic Letters*, **2011**, 13, 340-3	6.2	81
47	Copper-catalyzed tandem reaction of isocyanides with N-(2-haloaryl)propiolamides for the synthesis of pyrrolo[3,2-c]quinolin-4-ones. *Journal of Organic Chemistry*, **2011**, 76, 5346-53	4.2	43
46	Identification of pyrido[1,2-□pyrimidine-4-ones as new molecules improving the transcriptional functions of estrogen-related receptor □*Journal of Medicinal Chemistry*, **2011**, 54, 7729-33	8.3	47
45	BMPs functionally replace Klf4 and support efficient reprogramming of mouse fibroblasts by Oct4 alone. *Cell Research*, **2011**, 21, 205-12	24.7	102
44	Benzenediol-berberine hybrids: multifunctional agents for Alzheimer□s disease. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 7228-35	3.4	67
43	Synthesis of 1-Aryl-1H-indazoles via a Ligand-Free Copper- Catalyzed Intramolecular Amination Reaction. *Chinese Journal of Chemistry*, **2011**, 29, 1199-1204	4.9	22

42	Palladium-catalyzed amidation of N-tosylhydrazones with isocyanides. *Chemistry - A European Journal*, **2011**, 17, 12268-71	4.8	92
41	Hybrid compounds as new Bcr/Abl inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 1965-8	2.9	13
40	Structure-activity study on a series of □-glutamic acid scaffold based compounds as new ADAMTS inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 4457-61	2.9	9
39	Copper(I) Iodide Catalyzed Synthesis of Quinolinones via Cascade Reactions of 2-Halobenzocarbonyls with 2-Arylacetamides. *Synthesis*, **2011**, 2011, 1547-1554	2.9	4
38	Synthesis of 4-Oxoindeno[1,2-b]pyrroles through Copper-Catalyzed Tandem Reactions of 1-(2-Haloaryl)enones with Isocyanides. *Synthesis*, **2011**, 2011, 3037-3044	2.9	4
37	Rational optimization of reprogramming culture conditions for the generation of induced pluripotent stem cells with ultra-high efficiency and fast kinetics. *Cell Research*, **2011**, 21, 884-94	24.7	66
36	Towards an optimized culture medium for the generation of mouse induced pluripotent stem cells. *Journal of Biological Chemistry*, **2010**, 285, 31066-72	5.4	51
35	Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1. *Journal of Biological Chemistry*, **2010**, 285, 10273-80	5.4	114
34	Mild Conditions for Copper-Catalyzed N-Arylation of Imidazoles. *Synthesis*, **2010**, 2010, 1505-1511	2.9	4
33	GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. *Cancer Biology and Therapy*, **2010**, 9, 640-50	4.6	24
32	Synthesis of aza-fused polycyclic quinolines through copper-catalyzed cascade reactions. *Organic Letters*, **2010**, 12, 1500-3	6.2	66
31	Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. *Cancer Research*, **2010**, 70, 2516-27	10.1	249
30	Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. *ACS Medicinal Chemistry Letters*, **2010**, 1, 454-9	4.3	162
29	An Efficient Copper-Catalyzed Amination of Aryl Halides by Aqueous Ammonia. *Advanced Synthesis and Catalysis*, **2009**, 351, 1722-1726	5.6	100
28	Atovaquone derivatives as potent cytotoxic and apoptosis inducing agents. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 5091-4	2.9	19
27	(2-Pyridyl)acetone-promoted Cu-catalyzed O-arylation of phenols with aryl iodides, bromides, and chlorides. *Journal of Organic Chemistry*, **2009**, 74, 7187-90	4.2	104
26	2-Pyridinyl beta-ketones as new ligands for room-temperature CuI-catalysed C-N coupling reactions. *Chemical Communications*, **2009**, 1891-3	5.8	70
25	Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. *Journal of Medicinal Chemistry*, **2009**, 52, 7970-3	8.3	150

24	MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. *British Journal of Cancer*, **2009**, 101, 774-81	8.7	55
23	Assembly of indole-2-carboxylic acid esters through a ligand-free copper-catalysed cascade process. *Chemical Communications*, **2009**, 7581-3	5.8	58
22	Direct Oxidation of N-Benzylamides to Aldehydes or Ketones by N-Bromosuccinimide. *Synthetic Communications*, **2008**, 38, 1629-1637	1.7	7
21	A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy. *Cancer Biology and Therapy*, **2008**, 7, 845-52	4.6	27
20	l-Proline-Promoted Rosenmund-von Braun Reaction. *Synlett*, **2008**, 2008, 69-72	2.2	14
19	Recent Progress of Synthetic Studies to Peptide and Peptidomimetic Cyclization. *Current Organic Chemistry*, **2008**, 12, 1502-1542	1.7	50
18	Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 3933-8	11.5	574
17	Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. *Molecular Cancer Therapeutics*, **2008**, 7, 1533-42	6.1	69
16	Copper(I) Iodide Catalyzed Domino Process to Quinazolin-4(3H)-ones. *Synthesis*, **2008**, 2008, 3974-3980	2.9	5
15	An Efficient Synthesis of ABT-263, a Novel Inhibitor of Antiapoptotic Bcl-2 Proteins. *Synthesis*, **2008**, 2008, 2398-2404	2.9	2
14	Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins. *Journal of Medicinal Chemistry*, **2007**, 50, 3163-6	8.3	36
13	A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB)-induced apoptosis in leukemia cells. *Annals of Hematology*, **2007**, 86, 471-81	3	13
12	Room-Temperature Debenzylation of N-Benzylcarboxamides by N-Bromosuccinimide. *Synthesis*, **2007**, 2007, 3129-3134	2.9	5
11	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. *Journal of Medicinal Chemistry*, **2006**, 49, 456-8	8.3	18
10	Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. *Journal of Medicinal Chemistry*, **2006**, 49, 3432-5	8.3	581
9	Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 443-6	2.9	23
8	Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands. *Journal of Medicinal Chemistry*, **2005**, 48, 3171-81	8.3	24
7	Structure-based design of potent non-peptide MDM2 inhibitors. *Journal of the American Chemical Society*, **2005**, 127, 10130-1	16.4	543

6	Efficient synthesis of isoflavone analogues via a Suzuki coupling reaction. *Tetrahedron Letters*, **2005**, 46, 3707-3709	2	24
5	Synthesis of spirooxindoles via asymmetric 1,3-dipolar cycloaddition. *Tetrahedron Letters*, **2005**, 46, 5949-5951	2	51
4	Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 1701-5	2.9	19
3	An efficient synthesis of optically pure (S)-2-functionalized 1,2,3,4-tetrahydroquinoline. *Tetrahedron Letters*, **2004**, 45, 1027-1029	2	6
2	Asymmetric synthesis of α,α-disubstituted amino acids by diastereoselective functionalization of enantiopure phenyloxazinones, derivatives of asymmetric Strecker reaction products of aldehydes. *Tetrahedron*, **2001**, 57, 6361-6366	2.4	16
1	Synthesis of enantiopure alpha,alpha-disubstituted amino acids from the asymmetric Strecker reaction products of aldehydes. *Organic Letters*, **2000**, 2, 2515-7	6.2	23